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Galanin is a 29 amino acid peptide, initially isolated from the porcine small intestine. The peptide has been shown to 
occur in intrapancreatic nerves in close association to the islets. Its effects on islet hormone secretion and its possible 
mechanisms behind these effects are reviewed. Galanin has been shown to inhibit basal and stimulated insulin secretion 
both in vivo and in vitro under a variety of experimental conditions. The peptide has also been shown to inhibit somato- 
statin secretion and the secretion of pancreatic polypeptide (PP). With regard to glucagon secretion, however, results 
in the literature are not consistent since both stimulatory and inhibitory effects have been reported. A direct interaction 
with the pancreatic /&cells has been proposed behind its inhibitory action on insulin secretion, since galanin inhibits insu- 
lin secretion from isolated @ells from obese, hyperglycaemic, mice. Galanin has thereby also been shown to induce repo- 
larization and to reduce the free Caz+ concentration, [Caz+li. The reduction in [Ca2+li is probably not due to a direct 
interference with the voltage-activated Ca 2+ channels, since there is no effect of galanin when these channels are opened 
by depolarization induced by high concentrations of K +. Instead, preliminary studies indicate that galanin activates the 
K+ channels that are regulated by ATP, in turn inducing a repolarization-induced reduction in [Caz+], resulting in re- 
duced insulin secretion. However, the possibility that galanin inhibits the insulin secretory mechanism at a step distal 
to the regulation of cytoplasmic free Ca* + concentration should not be overlooked. 
Galanin; Insulin secretion; Glucagon secretion; Somatostatin secretion; Pancreatic polypeptide secretion; Caz+; 
(Pancreas, Islets of Langerhans) 
1. INTRODUCTION 
Galanin is a 29 amino acid peptide, initially 
isolated from the porcine small intestine [l]. The 
peptide is widely distributed within the body and 
exerts a variety of different effects [2]. In 1986, im- 
munocytochemistry revealed that galanin occurs in 
intrapancreatic nerves in the dog [3]. The nerves 
were observed in the endocrine as well as in the ex- 
ocrine portion of the pancreas and around blood 
vessels. However, the strongest fluorescence was 
consistently observed in close association with 
nerves innervating the pancreatic islets [3]. This 
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finding corroborated an earlier observation of 
galanin-like immunoreactivity in the rat and pig 
pancreas, as determined by radioimmunoassay [4]. 
The localization of galanin to intrapancreatic 
nerves stimulated a series of new investigations 
concerning its effects on islet function and galanin 
is now included in the neuropeptidergic oncept in 
the regulation of islet hormone secretion [5]. From 
the results obtained so far, it is clearly established 
that galanin has a major influence on islet hor- 
mone secretion under a variety of experimental 
conditions. Although the exact mechanisms 
mediating such an influence are poorly 
understood, recent studies have focussed the in- 
terest on the possibility of direct interference of 
galanin with basic biochemical, cell biological, and 
electrophysiological processes [6]. 
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2. BASAL PLASMA GLUCOSE AND 
INSULIN LEVELS 
The first indication of an effect of galanin on the 
endocrine pancreas was the demonstration of a 
hyperglycaemic action of the peptide in dogs [l]. 
After 60 min of intravenous infusion of galanin, at 
a rate of 10 pmol/kg per min, plasma glucose 
levels increased from 107 f 4 to 134 f 9 mg/dl 
[I]. McDonald et al. [7] also demonstrated that 10 
pmol/kg per min of galanin evoked a maximal 
elevation of basal plasma glucose levels, and that 
a lowering of basal plasma insulin levels occurred 
concomitantly with the hyperglycaemia. Two 
subsequent studies have reproduced these findings 
[3,8]. The threshold level for the effect of galanin 
in the dog was thereby found to be between 0.25 
and 2.5 pmol/kg per min [3]. To study whether the 
lowering of basal plasma insulin levels induced by 
galanin is due to a direct effect on the pancreas, the 
peptide was infused directly into the pancreatic 
artery at a dose level of 0.25 pmol/kg per min. 
Under such conditions, pancreatic insulin output 
decreased markedly (by 71 of: 2a), indicating that 
the observed lowering of basal plasma insulin 
levels in dogs is actually mediated by a direct in- 
hibition of pancreatic insulin secretion [3]. 
The effect of intravenously administered galanin 
on basal plasma levels of glucose and insulin has 
also been investigated in man, rats and mice. In 
man, however, galanin did not affect basal plasma 
glucose or insulin levels when infused at either 7.8 
or 33.2 pmol/kg per min [9]. In rats an intravenous 
infusion of galanin between 4 and 32 pmol/kg per 
min lowered basal plasma insulin levels but was 
without any effect on basal plasma glucose levels 
[lo]. Furthermore, at 5 min after an intravenous 
injection of galanin (2 nmol/kg) there was a mark- 
ed reduction in basal portal insulin levels [ 111, and 
at 3 min after an intravenous injection of the pep- 
tide at 22 nmol/kg, peripheral basal insulin levels 
were lowered [12]. In mice, galanin, injected in- 
travenously at dose levels between 0.53 and 8.5 
nmol/kg, induced hyperglycaemia and hypoin- 
sulinaemia [13]. Thus, studies performed in vivo in 
dogs and mice show that galanin induces 
hyperglycaemia nd hypoinsulinaemia, whereas in 
rats hypoinsuhnaemia without hyperglycaemia is 
seen, and in man, no influence has been observed 
on either basal plasma insulin or glucose levels. 
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3. STIMULATED PLASMA INSULIN LEVELS 
A few studies have been directed to the question 
of whether galanin, besides the lowering of basal 
plasma insulin levels, also inhibits stimulated 
plasma insulin levels. In dogs, intravenous infu- 
sion of galanin (20 pmol/kg per min) has thereby 
been shown to inhibit the plasma insulin response 
to intravenous administration of glucose or 
arginine or the oral administration of glucose or a 
mixed meal [7,14]. In rats, intravenous infusion of 
galanin (4-32 pmol/kg per min) has been 
demonstrated to reduce the plasma insulin 
responses to intravenously administered glucose or 
arginine [lo], and intravenous injections of galanin 
(2-22 nmol/kg) have been shown to reduce 
glucose-stimulated insulin secretion but to be 
without influence on the insulin response to gastric 
inhibitory polypeptide (GIP) [ 121. Furthermore, in 
mice, intravenous injection of galanin (1.1 or 4.3 
nmol/kg) inhibits the plasma insulin responses to 
intravenously administered glucose, carbachol 
(chohnergic agonist), terbutaline (,&-adreno- 
receptor agonist), or the octapeptide of cholecys- 
trokinin (CCK-8) [13,15]. In man, however, 
galanin infusion (33.2 pmol/kg per min) did not 
affect the glucose-induced increase in plasma in- 
sulin levels, although the glucose clearance was 
reduced by the peptide [9]. 
4. INSULIN SECRETION IN VITRO 
Since the infusion of galanin in the pancreatic 
artery markedly reduced basal pancreatic insulin 
output in dogs [3], it may be concluded that 
galanin lowers basal plasma insulin levels and 
reduces the insulin responses under a variety of 
stimulatory conditions by inhibiting insulin secre- 
tion. This conclusion has been supported by 
several in vitro studies. Thus, in the perfused 
canine pancreas, galanin (1 pM-10 nM) markedly 
reduced insulin secretion at 5.5 or 11.1 mM glucose 
in either the presence or absence of arginine (5 
mM) [16], and in the perfused rat pancreas, 
galanin (5 PM) reduced insulin secretion during ad- 
ministration of 5.5 mM glucose [17]. Also, in the 
latter case similar effects were obtained irrespec- 
tive whether arginine (10 mM) was present. Fur- 
thermore, galanin has also been demonstrated to 
inhibit insulin secretion from cultured rat islets (at 
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28 nM galanin and 6.7 mM glucose) [l l] and from 
freshly isolated rat islets (galanin at concentrations 
of 10 pM-1 pM and glucose at concentrations of 
5.5-16.7 n&I) [lo]. Theoretically, the inhibitory 
effects of galanin on insulin release from both the 
perfused pancreas and isolated islets might be in- 
direct. However, a direct inhibition by galanin of 
insulin secretion was finally demonstrated in a 
study on single pancreatic mouse P-cells (at 16 nM 
galanin and 20 mM glucose) [6]. Thus, studies 
presented so far clearly demonstrate that galanin is 
a potent inhibitor of both basal and stimulated in- 
sulin secretion in dogs, rats and mice, both in vivo 
and in vitro. Such an effect is likely, at least in 
part, to be exerted by a direct effect on the islet fl- 
cells. 
5. SOMATOSTATIN SECRETION 
Pancreatic somatostatin secretion in dogs in vivo 
has been demonstrated to be inhibited by galanin 
[3]. Also somatostatin secretion from the perfused 
canine pancreas in vitro has been shown to be 
markedly suppressed by galanin [16]. In dogs, the 
sensitivity to galanin of the somatostatin cells has 
been found to be slightly lower than that of the p- 
cells, since the threshold dose for galanin to inhibit 
insulin secretion was between 1 and 10 pM, 
whereas the corresponding value for somatostatin 
secretion was between 10 and 100 pM [16]. In con- 
tradistinction to these findings in the dog, a single 
study on the perfused rat pancreas showed no in- 
fluence of galanin (5 PM) on somatostatin secre- 
tion [17]. 
6. GLUCAGON SECRETION 
Initially, no influence on plasma glucagon levels 
was observed during intravenous infusion of 
galanin in dogs [7]. This finding was later confirm- 
ed in another study in dogs [8] and in work in man 
[9] as well as in rats [lo]. However, by the use of 
the more sensitive technique for determination of 
glucagon secretion in vivo, measurement of 
changes in plasma glucagon levels in the pancreatic 
vein during intrapancreatic administration of 
galanin, a stimulation of glucagon secretion could 
be demonstrated in dogs [3]. Similarly, in- 
travenously administered galanin, at high dose 
levels, increased plasma glucagon levels in mice 
[ 131. However, recently performed studies in vitro 
have not been able to confirm this conclusion; 
since galanin did not affect glucagon secretion 
from the perfused rat pancreas [17] and at high 
dose levels (10 nM), galanin was even found to in- 
hibit glucagon secretion from the perfused canine 
pancreas [16]. To what extent these apparent 
discrepancies can be accounted for by species dif- 
ferences is at the moment not known. However, 
differences due to experimental conditions should 
not be overlooked. In fact, in dogs galanin 
stimulates glucagon secretion in vivo [3] but in- 
hibits it in vitro [ 161. A possible explanation to this 
discrepancy might be a variation in sensitivity of 
the somatostatin cells to galanin. Noteworthy is 
that somatostatin secretion seems to be inhibited 
by galanin at comparatively lower doses in vivo [3] 
than in vitro [ 161, and consequently, that glucagon 
secretion might be more readily stimulated in vivo 
due to lower local levels of somatostatin. 
7. PANCREATIC POLYPEPTIDE (PP) 
SECRETION 
During intravenous galanin infusion in man 
(33.2 pmol/kg per min), plasma levels of PP were 
reduced [9] indicating an inhibition of PP secre- 
tion. Since galanin in the same experiment did not 
affect plasma insulin levels [9] it could be conclud- 
ed that in man, the secretion of PP is more sen- 
sitive to galanin than is that of insulin. A recent 
study on the perfused rat pancreas has, similarly, 
shown that galanin inhibits PP secretion [18]. 
8. MECHANISM OF ACTION 
From what has been discussed so far, it is ob- 
vious that the most pronounced effect of galanin in 
the endocrine pancreas is its inhibition of insulin 
release. Since galanin inhibits insulin release evok- 
ed by various secretagogues, such as glucose, 
arginine, carbachol, terbutaline, cholecystokin as 
well as oral intake of glucose or mixed meal 
[7,10,12,13], it is likely that galanin stimulation in- 
terferes with a central step in the insulin secretory 
machinery. When trying to establish the exact 
mechanisms, it has been demonstrated that neither 
does the peptide influence pancreatic venous levels 
of noradrenaline [3] nor are its effects on insulin 
release affected by adrenergic blockade [la]. 
235 
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Hence, it is not likely that the effects of galanin on 
the &cells are mediated through either activation 
of adrenergic nerves or interaction with en- 
dogenous adrenoceptors. That the effects of 
galanin indeed can be accounted for, at least in 
part, by a direct interaction with the pancreatic ,d- 
cells has recently been demonstrated, using a 
suspension of &cells isolated from obese, 
hyperglycaemic, mice [6]. Since insulin release is a 
Ca2+ regulated process, it is of interest o note that 
galanin-induced inhibition of glucose-stimulated 
insulin release is paralleled by both a repolariza- 
tion and a reduction in free cytoplasmic Ca2+ con- 
centration, [Ca2+ ]i [a]. The reduction in [Ca2’]i is 
probably not due to a direct interference with the 
voltage-activated Ca” channels, since there is no 
effect of galanin when these channels are opened 
by depolarization induced by high concentrations 
of K+ [6]. Hence, the reduction in [Ca2+]i probably 
results from a repolarization-induced closure of 
the voltage-activated Ca2+ channels. Noteworthy is 
that galanin has similar effects to the 
hyperglycaemic sulphonamide diazoxide on mem- 
brane potential, [Ca”]i and insulin release [6,19]. 
The pronounced repolarization induced by both 
diazoxide and galanin is difficult to reconcile with 
anything but an activation of some sort of K+ 
channels. With regard to d&oxide, it is indeed 
clearly established that this compound exerts its 
repolarizing effect through an activation of the 
ATP-regulated K+ channels in &cells [ 19,201. To 
what extent the repolarizing effects of galanin can 
be explained in terms of a similar activation of the 
ATP-regulated K+ channels has up to now been 
more uncertain. However, preliminary data [21] 
indicate that galanin actually activates K+ channels 
of similar characteristics to those regulated by 
ATP [19], i.e. a single conductance of about 60 pS. 
Whether galanin in addition activates some other 
types of K+ channels can so far just be a matter of 
speculation. The reduction in [Ca”]i subsequent 
to the repolarization is then probably, at least to a 
major extent, responsible for the suppression of in- 
sulin release. However, at this point we cannot ex- 
clude the possibility that galanin also interacts with 
more distal steps in the stimulus-secretion cou- 
pling. 
In fig.1 the possible mechanisms whereby 
galanin evokes its inhibitory effect on insulin 
release are outlined. The decrease in [Ca2’]; might 
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Fig. 1. Effects of galanin on pancreatic &cells and the possible 
mechanisms whereby these effects are exerted. IC, PM, and EC 
denote intracellular, plasma membrane, and extracellular, 
respectively. Solid arrows represent known mechanisms 
whereas dashed arrows indicate possible mechanisms. 
result from either a repolarization-induced closure 
of the voltage-activated Ca2+ channels, implying 
that galanin activates ome sort of K+ channels, or 
a direct interference with the Ca2+ channels, 
although, as discussed above, the possibility that 
galanin inhibits the insulin secretory mechanism at 
a step distal to the regulation of [Ca2’]i should not 
be overlooked. Hence, the final understanding of 
both the exact mechanisms whereby galanin 
regulates membrane potential and [Ca2+]i and the 
extent to which a reduction in [Ca2’]i can explain 
the interference with the insulin secretory 
mechanism awaits future more sophisticated 
biochemical, cell biological and electrophysiologial 
studies. 
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